Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

152.00 -10.57 (-6.50%)
Streaming Delayed Price Updated: 3:35 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
8 Analysts Have This To Say About Natera
Via Benzinga
Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales
Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2025, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98... 
Via StockStory
Natera Reports First Quarter 2025 Financial Results
From Natera, Inc.
Via Business Wire
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
From Natera, Inc.
Via Business Wire
Earnings Scheduled For May 8, 2025
Via Benzinga
Preview: Natera's Earnings
Via Benzinga
Peering Into Natera's Recent Short Interest
Via Benzinga
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
From Natera, Inc.
Via Business Wire
What To Expect From Natera’s (NTRA) Q1 Earnings
Genetic testing company Natera (NASDAQ:NTRA). will be reporting earnings tomorrow after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera
From Natera, Inc.
Via Business Wire
Natera to Report its First Quarter Results on May 8, 2025
From Natera, Inc.
Via Business Wire
Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction
From Natera, Inc.
Via Business Wire
2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
Via Benzinga
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test
From Natera, Inc.
Via Business Wire
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
From Natera, Inc.
Via Business Wire
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 to Turn Down
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
Via Benzinga
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences. 
Via Investor's Business Daily
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Assessing Natera: Insights From 10 Financial Analysts
Via Benzinga
3 Reasons NTRA Has Explosive Upside Potential
Natera currently trades at $141.03 and has been a dream stock for shareholders. It’s returned 351% since April 2020, blowing past the S&P 500’s 87.1% gain. The company has also beaten the index over... 
Via StockStory
Topics Government Stocks
Exposures Political US Equities
27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is the Market Bullish or Bearish on Natera?
Via Benzinga
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
From Natera, Inc.
Via Business Wire
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
Via The Motley Fool
1 Mid-Cap Stock to Own for Decades and 2 to Brush Off
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.